Deferoxamine prevents dexamethasone-induced muscle atrophy by reducing MuRF1 and atrogin-1.

ABSTRACT:

Introduction

Muscle atrophy, commonly triggered by glucocorticoids such as dexamethasone (DEX), involves increased protein degradation via the ubiquitin-proteasome system. Recent findings suggest that iron imbalance can also induce muscle atrophy. However, there have been no reports indicating that DEX causes intracellular iron imbalance leading to muscle atrophy. This study evaluated whether DEX causes iron imbalance-mediated muscle atrophy and whether deferoxamine (DFO), an iron chelator, can protect against DEX-induced muscle atrophy, exploring the underlying mechanisms in vitro and in vivo.

Method

Differentiated C2C12 myotubes were exposed to DEX, with or without DFO, to evaluate morphological changes, expression of muscle-specific ubiquitin ligases (atrogi

SUBMITTER: Jeong JY 

PROVIDER: S-EPMC12283682 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature